Phase 2
N=52
Modulation of Lung Injury Complicating Lung Resection
Acute Lung Injury
Bottom Line
View on ClinicalTrials.gov: NCT00655928 ↗Enrolled (actual)
52
Serious AEs
55.3%
Results posted
Sep 2019
Primary outcome: Primary: Post-operative Plasma IL-6 — 126; 111 pg/ml — p=0.09
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- N-acetylcysteine (Drug); 0.9% saline (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Imperial College London
- Primary completion
- Jul 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Post-operative Plasma IL-6 |
126; 111 | 0.09 |
Summary
The purpose of this study is to determine whether N-acetylcysteine given intravenously 1 day pre-operatively is effective in preventing inflammation in the lungs, as measured by tests on blood, breath and lung specimens, in patients undergoing surgery to remove a portion of lung.
Eligibility Criteria
Inclusion Criteria
- Elective lung resection for cancer
Exclusion Criteria
- Age less than 18 years
- Women of child-bearing age or potential
- Known allergy to N-acetylcysteine
- Oral steroid in the preceding 1 month
- N-acetylcysteine in the preceding 1 month
- Unable to receive standardised anaesthetic approach
Data sourced from ClinicalTrials.gov (NCT00655928). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.